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Abstract Oral mucositis induced by conventional cytotoxic
cancer therapies is a common and significant clinical problem
in oncology. Mucositis symptoms, which include severe pain,
may lead to dose reductions and unplanned interruptions of
chemotherapy and/or radiotherapy, and often affect patients'
quality of life. In addition, ulcerative mucositis represents a
risk factor for local or systemic infectious complications that
may be life-threatening in immunosuppressed patients. The
development of biologically based targeted cancer therapies,
which aim to block the growth, spread, and survival of tumors
by interfering with specific molecular targets, may have re-
duced mucosal injury, but did not eliminate it. This article will
review the epidemiology, pathobiology, and management of
oral mucositis associated with conventional cytotoxic thera-
pies for malignant diseases and will briefly summarize emerg-
ing information on oral mucosal injury associated with
targeted therapies. Considerations for future research aimed
at the development of more efficient and effective supportive
care approaches will be presented, with emphasis on the con-
tribution of dental researchers and clinicians in these efforts.
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Introduction
Oral mucositis (OM), an inflammatory condition of the oral
and oropharyngeal mucosa induced by cytotoxic chemother-
apy and/or radiotherapy, represents a major clinical problem in
oncology. In its most severe form, OM presents as confluent,
deep ulcerations. Pain associated with mucositis often impairs
a patient’s functional status and quality of life [1–3]. In pa-
tients treated with chemotherapy alone or combined chemora-
diation regimens, the whole gastrointestinal tract may be af-
fected. Weight loss is common, and patients may require
gastrostomy or parenteral feeding. Severe OM may lead to
dose reductions and unplanned interruptions of cancer thera-
pies. In addition, ulcerative mucositis, characterized by dis-
ruption of the integrity of the epithelial barrier, represents a
significant risk factor for systemic infectious complications,
particularly in neutropenic or otherwise immunocompromised
patients. These clinical consequences are associated with in-
creased use of healthcare resources andmay negatively impact
survival [4].
Despite major progress in our understanding of the patho-
biology of chemotherapy and/or radiotherapy-induced muco-
sitis, and the availability of interventions in selected patient
populations, OM and its associated symptoms still represent
an unmet need [5•].
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Recently, major advances have been achieved in the field
of biologically based therapies for cancer. These novel
Btargeted^ approaches aim to block the growth, spread, and
survival of tumors by interfering with specific molecular tar-
gets, and include hormone receptor-blocking therapies, signal
transduction inhibitors, gene expression modulators, apopto-
sis inducers, angiogenesis inhibitors, immune response en-
hancers, and toxin delivery molecules [6]. A substantial num-
ber of targeted drugs have been approved by regulatory au-
thorities for the treatment of a variety of malignancies, and can
be used alone or in combination with conventional cytotoxic
anticancer therapies [7••].
As expected, targeted cancer therapies are generally less
toxic to normal cells than traditional chemotherapy drugs.
However, it has become increasingly clear that targeted cancer
therapies can have substantial side effects, including effects on
oral tissues [8]. The clinical features of oral lesions induced by
some of these new therapies differ from those of conventional
OM, and the current understanding of their pathobiological
pathways is limited.
This narrative review paper will focus on OM associated
with conventional malignant disease therapies, and we will
briefly summarize emerging information on oral lesions asso-
ciated with targeted therapies. In addition, we will present
considerations for future research aimed at developing more
efficient and effective supportive care approaches, with em-
phasis on the contribution of dental researchers and clinicians
in these efforts.
Oral Mucositis Among Different Types of Cytotoxic
Treatment
Prevalence and incidence data on OM vary considerably. Rea-
sons for inconsistencies include a heterogeneity of standard-
ized scoring criteria, variation among tumor type locations,
and different treatment regimens [9••]. In addition, there
may be genetic and ethnic differences among patients in stud-
ies performed in different parts of the world. Moreover, most
data are derived from clinical trials in which OM was not a
primary study endpoint, and therefore its frequency is likely
underreported. On the other hand, OM can be easily confused
with infections or other oral mucosal conditions, which may
have also affected figures reported in the literature.
Oral Mucositis Associated with Hematopoietic Stem Cell
Transplantation
Oral mucositis (any grade) develops in approximately 75% to
100 % of patients undergoing myeloablative autologous (with
the patient’s own stem cells) or allogeneic (with donor-derived
stem cells) hematopoietic stem cell transplantation (HSCT)
[10]. Myeloablative conditioning regimens cause irreversible
pancytopenia, and stem cell support is required to rescue mar-
row function in order to prevent aplasia-related death [11].
Prospective studies have reported that conditioning regimens
containing high-dose melphalan, busulfan, and/or cyclophos-
phamide, with or without total body irradiation (TBI), were
associated with severe OM [12, 13]. The incidence of severe
OM (WHO grades 3–4) may be lower for individuals treated
with conditioning protocols without TBI [14••]. A large pro-
spective European study found that 67% ofmultiple myeloma
patients treated with high-dose melphalan followed by autol-
ogous HSCT developed ulcerative OM (WHO grade≥2),
whereas ulcerative OM occurred in 60 % of non-Hodgkin’s
lymphoma patients treated with carmustine, etoposide,
cytarabine, melphalan (BEAM) chemotherapy, and autolo-
gous HSCT [15].
Over the last two decades, less toxic conditioning regimens
have been introduced, based on observations that
alloreactivity of transplanted donor immunocompetent cells
against host tumor cells (graft-versus-tumor/leukemia effect)
plays a major role in eradicating malignancies, thus expanding
the availability of HSCT to older patients and those with co-
morbidities. Non-myeloablative (NMA) conditioning proto-
cols are the mildest form, typically causing minimal pancyto-
penia but considerable immunosuppression, allowing full en-
graftment of donor cells. Reduced-intensity conditioning reg-
imens (RIC) form an intermediate category of therapy. RIC
regimens differ from myeloablative conditioning in that the
dose of chemotherapy agents and/or TBI is reduced by at least
30 %. Both NMA and RIC regimens are associated with re-
duced incidence and severity of OM [16, 17]. However, allo-
geneic transplant patients thus treated require graft-versus-
host disease prophylaxis, which may increase the risk of
OM. There are relatively scant data on the incidence and se-
verity of OM associated with NMA and RIC.
Chemotherapy-Induced Oral Mucositis
The frequency of chemotherapy-induced OM in patients with
solid tumors is not well documented, and varies significantly
among various studies [18, 19]. One explanation for the di-
vergent findings may be that most studies follow patients only
during their first cycle of chemotherapy, whereas the inci-
dence of mucositis may increase significantly in subsequent
cycles due to cumulative effects. For example, among com-
mon chemotherapy regimens in breast cancer, ulcerative OM
was reported in about 20 % of patients during the first cycle of
treatment. If these patients received the same dose of the same
drugs in a second cycle, the frequency of OM increased to
70 % [20]. In patients undergoing chemotherapy treatment
regimens for lymphoma or solid tumors, 20 % to 40 % devel-
oped any grade of OM [21–23]. A systematic review evaluat-
ing multiple studies reported that standard chemotherapy reg-
imens for non-Hodgkin’s lymphoma occasionally resulted in
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severe OM (3–10 %), and similar rates were observed in
breast cancer patients treated with doxorubicin- and taxane-
based regimens [18]. In addition, patients with lung cancer
who received platinum-based chemotherapy and patients with
advanced colorectal cancers treated with standard regimens
containing 5-fluorouracil were at low risk for severe OM. In
a recent prospective study involving 298 patients treated with
myelosuppressive chemotherapy for solid tumors, 120 pa-
tients (40.3 %) developed WHO grade 1 OM, 15 patients
(5 %) showed WHO grade 2, and only 3 patients (1 %) had
severe OM (WHO grades 3–4) [24•]. It should be noted, how-
ever, that even mild mucositis may represent a burden to
patients.
Radiotherapy-Induced Oral Mucositis
In patients undergoing radiation therapy for head and neck
cancer (HNC), OM is a frequent toxicity, affecting almost all
patients in which areas of the oral or oropharyngeal mucosa
are included in the treatment field. Sutherland and colleagues
reported that approximately 60 % of patients receiving stan-
dard radiotherapy developed severe OM [25]. In advanced
HNC (about 60 % of clinical presentations), combined che-
moradiation has been associated with improved locoregional
disease control and organ preservation, and has become an
accepted standard of care for tumors that cannot be removed
surgically, or for cases in which surgery causes unacceptable
changes to speech or swallowing [26–28]. However, this is at
the cost of greater toxicity, including severe OM.
In a systematic review of 33 studies involving 6181 pa-
tients, in which the incidence of OM was investigated in pa-
tients treated with different radiation therapy modalities as
well as chemoradiation, the mean incidence of OMwas found
to be 80 % [29]. Over one-half of patients (57 %) who re-
ceived altered fractionation radiotherapy experienced severe
OM, compared to 34% of patients who received conventional
radiotherapy and 43 % of patients treated with combined che-
moradiation protocols. Rates of hospitalization due to OM
reported in three studies were 16 % overall and 32 % for
patients treated with altered fractionated protocols. Eleven
percent of patients had OM sufficiently severe to interrupt
radiation therapy.
Vera-Llonch and colleagues conducted a retrospective
study to evaluate the incidence and clinical impact of OM in
450 patients receiving radiotherapy for HNC [30], reporting
the occurrence of OM in 83 % of patients, among which 29 %
of cases were severe. Severe OM was associated with treat-
ment breaks and hospitalization, and was more likely to occur
in patients with nasopharyngeal carcinoma or oropharyngeal
tumors who received concomitant chemotherapy. Elting and
coworkers reported virtually identical incidence of OM in pa-
tients with oral cavity or oropharynx tumors (99 % overall;
85 % grade 3–4) and those with tumors of the larynx or
hypopharynx (98 % overall; 77 % grade 3–4). In this prospec-
tivemulticenter study, patients received a cumulative radiation
dose of least 40 Gray (Gy) in single daily fractions, with or
without subsequent boost and/or chemotherapy [3].
Conventional 2D and 3D radiotherapy uses large fields and
a series of field reductions to provide sequentially higher
doses to the primary tumor. Intensity-modulated radiotherapy
(IMRT) has emerged as an effective technique for delivering
the full radiation dose to the tumor and regions at risk while
reducing exposure to healthy tissues. The effect of IMRTwas
examined in 160 HNC patients to determine whether it could
reduce the incidence and/or severity of OM and consequent
dose delays and reductions [31]. Patients were treated with
standard radiotherapy or IMRT, with or without chemothera-
py. Mucositis occurred in 97–100 % of patients, among
which≥69 % developed severe OM. Although there was a
trend toward decreased incidence of severe OM in patients
who received IMRT compared with standard radiotherapy,
there was no significant difference in dose delays or reduc-
tions. Another study of 158 HNC patients reported that more
patients treated with conventional radiotherapy exhibited OM
compared with those treated with IMRT (46.5 % versus
16.9 %) [32].
The addition of epidermal growth factor receptor (EGFR)-
targeted therapies to radiotherapy regimens has improved
treatment outcomes [33]. Combined treatment with cetuximab
and IMRTwas found to be more likely to cause acute adverse
events, including OM, in patients with nasopharyngeal carci-
noma than protocols with induction chemotherapy followed
by concomitant cisplatin and IMRT [34].
Risk Factors
There are still many unanswered questions about the risk fac-
tors for developing OM, but historically, risk factors have
been attributed to both therapy and patient characteristics
[35]. As mentioned above, treatment variables that may affect
the incidence and the severity of OM include the type, dose,
and schedule of systemic cytotoxic drugs delivered, radiation
dose and field, and concomitant use of chemotherapy and
radiation. Studies have shown that the risk of OM increases
as the intensity of therapy increases [36].
Patient-related risk factors are more complex and, for the
most part, are poorly defined. Despite similarities in diagnosis
and treatment, patients are not at equal risk of developing
mucositis. Among patient-associated factors, age, malnutri-
tion, gender, pre-existing medical conditions, alterations in
salivary production and composition, poor oral health, and
mucosal trauma have been reported to influence the risk of
OM (reviewed in [37]). Poor dental health, particularly peri-
odontal disease, has been identified as an environmental factor
that may increase the severity of OM (discussed in more detail
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below) [24•, 38]. Reducing oral bacterial load and periodontal
inflammation was associated with a lower prevalence of OM
in HSCT recipients [39–41]. There has been increased interest
recently in the role of the oral microbiome in OM risk [42, 43•,
44••], with studies suggesting that shifts in the composition of
the oral microbiome during chemotherapy influence OM se-
verity [45]. Porphyromonas gingivalis and other periodontal
pathogens have been identified as explanatory variables for
oral ulcerations [46]. In addition, fungi and viruses that are
typically associated with mucosal injury have been studied for
their potential involvement in the development of ulcerative
OM, but no firm conclusions can be drawn [46–50].
Genomic differences, which are major determinants of tox-
icity risk, have been identified among patients with head and
neck cancer who received radiotherapy [20, 51–53]. Genetic
determinants of chemotherapy-induced risk of mucositis in-
clude genes that regulate the availability of active drug metab-
olites. For example, evaluation of genetic variations in folate-
metabolising enzymes may help in identifying patients at
greater risk for methotrexate toxicity, although enzyme defi-
ciencies may be relatively rare. In contrast, differences in the
expression of genes associated with biological pathways that
drive mucositis are more common. For instance, genetic poly-
morphisms associated with the expression of inflammatory
mediators such as TNF-α have been implicated in OM risk
[54]. The tumor itself has recently become appreciated as
playing a role in OM risk [20, 55]. The inflammatory response
induced by the tumour, together with inflammation from
treatment-induced cytolysis, may contribute to adverse events,
including OM [56••].
Pathobiology
The cytotoxic effects of antineoplastic therapies are not limit-
ed to tumor cells, but also affect normal tissues. Historically,
OM was viewed exclusively as the result of nonspecific toxic
effects of radiation and/or chemotherapy on rapidly prolifer-
ating basal epithelial cells, resulting in clonogenic cell death
and consequently in tissue atrophy and ulceration. However,
animal studies have indicated that the pathobiology of OM is
much more complex, which prompted prompt Sonis to pro-
pose a model involving connective as well as epithelial tissues
[57]. This five-phase model describes a cascade of interrelated
and overlapping events. Phases include initiation, upregula-
tion and activation, signal amplification, ulceration, and
healing.
The initiation phase is characterized by radio- and/or
chemotherapy-induced DNA and non-DNA damage that re-
sults in injury of basal epithelial, submucosal, and endothelial
cells. These cells release endogenous damage-associated mo-
lecular patterns (DAMPs), which then bind to specific recep-
tors and play an integral role in initiating inflammation
toxicity [58]. In response to this damage, oxidative stress re-
sults in the formation of reactive oxygen species (ROS) inside
injured cells. ROS further damage cell membranes, stimulate
macrophages, and trigger molecules that activate transcription
factors, including nuclear factor (NF)-κB [59]. NF-κB can be
considered the Bgatekeeper^ for inflammatory pathways in-
volved in mucositis. Its activation precedes peaks in proin-
flammatory cytokines such as tumor necrosis factor (TNF)-α,
in te r leuk in ( IL) -6 , and IL-1β , and upregula tes
cyclooxygenase-2 (COX-2) in submucosal fibroblasts and en-
dothelial cells [60–62].
Many of the molecules induced by this primary response
have the ability to alter the local tissue response through feed-
back loops. For example, TNF-α activation may generate
positive feedback on NF-κB to amplify its response (signal
amplification phase) and initiate mitogen-activated protein ki-
nase (MAPK) signaling, leading to activation of c-Jun N-ter-
minal kinase (JNK) signaling [63]. NF-κ B independent path-
ways such as the ceramide pathway also play a role, resulting
in apoptosis of submucosal and basal epithelial cells, leading
to mucosal ulceration (ulcerative phase). Recent studies sug-
gest the involvement of deregulated expression of metallopro-
teinases (MMPs) in the pathobiology of mucositis [62, 64•].
The ulcerative phase comprises loss of mucosal integrity
and microbiological colonization by oral bacteria. Bacterial
cell wall products are capable of extending mucosal damage
as they stimulate infiltrating macrophages to produce addi-
tional pro-inflammatory cytokines.
Healing of ulcerations is associated with epithelial prolif-
eration, often concurrent with hematopoietic recovery, rees-
tablishment of local microbial flora, and absence of factors
that interfere with wound healing such as infection and me-
chanical irritation [65]. The extracellular matrix (ECM) is a
complex structural network of fibrous proteins, proteoglycans,
and glycoproteins that plays a role in signaling between tis-
sues. ECM stimulates epithelial cell migration, proliferation,
and differentiation, leading to renewal of the mucosa. [66].
Presentation and Clinical Course of Oral Mucositis
While there is similarity in the cellular events of
chemotherapy-induced and radiation-induced OM, there are
differences in the kinetics of treatment, affecting the clinical
course (Fig. 1). Among patients receiving cycled chemother-
apy or conditioning regimens before HSCT, the first signs of
OM usually begin about 3–4 days after drug infusion, and
ulcer formation begins shortly thereafter. OM peaks about 7
to 14 days later, and then resolves within another 5–10 days.
Radiotherapy-induced OM has a more gradual clinical
course, as radiotherapy is typically administered in small frac-
tions with a total of about 10 Gy per week, and continues until
a total dose of 60 to 70 Gy has been delivered. Clinical signs
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of OM generally appear at cumulative doses of about 15 Gy,
and reach full severity at 30 Gy. Nowadays, patients may
receive treatment involving chemoradiation regimens (usually
with cisplatin or carboplatin) or radiotherapy with concurrent
cetuximab, which are associated with increased OM severity
[67–69]. Ulcerations typically resolve 2–4 weeks after the
completion of therapy, but may last longer in some patients.
In both chemotherapy- and radiotherapy-induced OM, mu-
cosal erythema is often the first manifestation, and it may be
accompanied by feelings of burning. In patients who receive
chemotherapy for the treatment of solid tumors, OM may not
progress to severe forms. However, many patients develop
one or more deep ulcerations that may be covered with a
pseudomembrane. Their borders are generally poorly defined
and do not display peripheral erythema. Ulcer development is
associated with increased pain, since epithelial cell loss results
in the exposure of the richly innervated underlying connective
tissue. OM often impairs food intake.
OM lesions are most frequently found on the buccal and
labial mucosa, lateral and ventral tongue, floor of the mouth,
and the soft palate. The more heavily keratinized mucosal
surfaces are usually spared by OM, but may be affected by
viral and/or fungal diseases (Herpesviridae family, candida
spp.).
Stomatitis Associated with Targeted Therapies
Targeted anticancer agents influence or inhibit the signaling of
many cellular targets, including mammalian target of
rapamycin (mTOR), EGFR, vascular endothelial growth fac-
tor receptor (VEGFR), human epidermal growth factor recep-
tor (EGF)-2, and several (multi-targeted) tyrosine kinases.
Many monoclonal antibodies and small molecule inhibitors
are now used to improve survival for a wide variety of
malignancies.
Oral toxicities caused by these agents differ clinically, and
likely also pathobiologically, from conventional OM. There-
fore, the broader term Bstomatitis^ is preferred to Bmucositis^
for describing the mucosal injuries and other oral toxicities
(e.g., mucosal sensitivity, taste alterations, dry mouth,
gingival/jaw bone necrosis) associated with selected targeted
agents [70–73]. Although oral mucosal lesions are usually
mild and self-limiting, lesions may persist over long periods,
presenting a significant burden to patients.
The prevalence of oral toxicities (any grade) has been re-
ported at 38 % for sunitinib, 28 % for sorafenib, and 4 % for
pazopanib in patients with renal cancer [71]. In meta-analyses
conducted by Elting and coworkers, stomatitis was most fre-
quently reported among patients treated with bevacizumab,
erlotinib, sorafenib, or sunitinib [74].
mTOR inhibitors (everolimus and temsirolimus) are ap-
proved for the treatment of renal cell cancer and selected other
malignancies. mTOR inhibitor-associated stomatitis (mIAS)
resembles aphthous stomatitis, characterized as distinct ovoid
ulcers with a central gray area surrounded by a ring of erythe-
ma [70]. These lesions typically present with a rapid onset
(usually within 5 days), most frequently in the first cycle of
therapy. Similar to conventional OM, mIAS almost exclusive-
ly affects the non-keratinized, movable oral surfaces. Even
small ulcerations can cause significant pain, and mucosal sen-
sitivity may occur in the absence of clinical changes. The use
of assessment tools driven primarily by ulceration size may
underestimate mIAS, and assessment should include patient-
reported outcomes [75]. In a systematic review evaluating 44
studies, mIAS was identified as the most frequent adverse
event overall (73.4 %), accounting for 27.3 % of dose reduc-
tions and 13.1 % of therapy discontinuation [76].
Management Considerations
Conventional Oral Mucositis
Mucositis management relies on symptom management and
prevention of complications, which includes pain control, nu-
tritional support, and prophylaxis/treatment of secondary in-
fections [77]. Although these components continue to be of
great importance, research has also identified a number of
specific strategies to prevent the onset or reduce the severity
of OM. Clinical practice guidelines have been prepared for the
management of OM based on evidence and expert opinion
[78–80]. The Multinational Association of Supportive Care
in Cancer/International Society of Oral Oncology (MASCC/
ISOO) recommends or suggests (depending on the level of
supporting evidence) interventions for the prevention or treat-
ment of OM in specific patient populations. Oral care is a key
Fig. 1 Clinical differences in onset, severity, and resolution of
chemotherapy- and radiation-induced oral mucositis. In some patients
treated with radiotherapy, oral mucositis may last for longer periods and
may become chronic. Hyperfractionated radiotherapy, combined
chemoradiation regimens, or radiotherapy combined with a targeted
agent may lead to increased mucositis severity (not depicted)
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factor in the prevention and mitigation of oral injury; thus,
reducing the microbial load and educating the patient regard-
ing oral hygiene is very important. Other preventive measures
include cryotherapy, keratinocyte growth factor-1, low-level
laser therapy, benzydamine mouthwash, and zinc (Table 1).
Stomatitis
There are no evidence-based guidelines for the management
of mucosal lesions associated with targeted therapies. Man-
agement begins with assessment and oral hygiene measures,
diet modifications, and pain management. In most cases, pain
can be controlled with locally applied products containing
lidocaine or doxepin and mucosal coating agents. In persistent
cases, treatment with local or systemic corticosteroids can be
considered [75]. Secondary candidiasis is a common side ef-
fect of topical steroid therapy. If this occurs, topical antifungal
therapy should be initiated. However, systemically absorbed
azole antifungal agents may increase the toxicity of mTOR
inhibitors.
Future Research Directions
Progress in mucositis research largely relies on investigations
aimed at identifying potential targets for preventive and ther-
apeutic interventions. A number of agents are at various stages
of clinical development, and studies are underway on novel
delivery mechanisms and risk prediction models that can fa-
cilitate the selective use of interventions in a cost-effective
manner [5•]. Here we will discuss some potential lines of
approach in which cross-pollination between recent concepts
in oral/periodontal medicine and mucositis research may lead
to new insights and points of departure for future studies.
There is evidence to suggest (albeit from small studies) that
an infected and inflamed periodontium is associated with in-
creased severity of OM [24•, 38–41, 81]. Well-powered pro-
spective observational studies in homogenous groups of pa-
tients, using well-defined parameters for the assessment of
OM and periodontal disease, are necessary to substantiate this
association.
Interestingly, it has been proposed that the presence of in-
flammation (anywhere in the body) primes for a dysregulated
and exaggerated inflammatory response following a subse-
quent inflammatory stimulus [82]. This Btwo-hit model^ has
been hypothesized to underpin an association between peri-
odontitis and OM [83•]. The authors postulated that pre-
existing periodontitis may co-induce an exaggerated inflam-
matory response following radiotherapy in patients with
HNC, leading to more severe OM. In turn, OM may contrib-
ute to the severity of periodontitis. Taking this hypothesis one
step further, it seems feasible that not only may periodontitis
serve as a Bfirst hit^ for mucositis, but that any oral or non-oral
inflammatory-driven toxicity may co-induce other inflamma-
tory complications (e.g., cachexia, fatigue, systemic inflam-
matory response syndrome). This theory may also explain the
well-documented observation that cancer regimen-related tox-
icities do not occur in isolation, but rather develop in non-
random clusters [55, 84, 85]. Moreover, a patient’s risk of
developing both periodontitis and inflammatory-driven toxic-
ities may be linked by a genetic predisposition to express
increased levels of inflammatory mediators. These intriguing
hypotheses deserve further exploration.
In addition, investigations should be performed to further
characterize the role of the oral environment. This includes
studies on the potential contribution of the oral/periodontal
microbiome in the pathobiology of OM and stomatitis associ-
ated with targeted therapies using next-generation sequencing
techniques. Similarly, studies on changes in salivary output
and salivary proteome induced by cancer therapies may con-
tribute to a scientific base for OM risk prediction, early diag-
nosis, and interventions.
Furthermore, there is a pressing need for clinical practice
guidelines for periodontal management in cancer patients,
from diagnosis through survivorship. In particular, strategies
are needed for effectively minimizing periodontal infection
and inflammation in these often medically compromised pa-
tients. In addition to debridement, approaches directed toward
reducing periodontal inflammation seem to hold promise [86].
Among other strategies, adjunctive host modulation therapy
developed for periodontitis (i.e., sub-antimicrobial-dose doxy-
cycline alone or in combination with an anti-inflammatory
agent) may simultaneously mitigate both periodontitis and
other inflammatory conditions [87••]. These interventions
may open new avenues for the management of periodontitis,
but may also positively affect OM and other inflammatory
complications associated with cytotoxic cancer therapies.
Conclusions
Oral mucosal toxicities associated with antineoplastic thera-
pies continue to represent a significant oncological challenge.
While our understanding of oral adverse effects associated
with targeted therapies is still in its infancy, and knowledge
of the epidemiology of OM is incomplete, significant progress
has been made in unraveling the pathogenesis of OM, and
some preventive approaches have been identified. Neverthe-
less, for the majority of patients, no effective interventions are
available.
Researchers and clinicians in the field of cancer regimen-
related toxicities and those involved in oral and periodontal
medicine should join forces in pursuit of understanding and
developing strategies for treatment of inflammatory condi-
tions in oncology. Ultimately, this will lead to effective
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Table 1 Multinational Association for Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) Clinical Practice
Guidelines for Oral Mucositis. Modified from [78]
Intervention/mode of administration Purpose Cancer treatment Level of
evidence
Recommendations IN FAVOR of an intervention (strong evidence supports effectiveness in the treatment setting listed):
Oral cryotherapy for 30 minutes Prevention of
OM
Patients receiving bolus 5-fluorouracil chemotherapy Level II
Recombinant human keratinocyte growth factor-1
(palifermin) at a dose of 60 μg/kg per day for
3 days prior to conditioning treatment and for
3 days after transplant
Prevention of
OM
Patients receiving high-dose chemotherapy and TBI,
followed by autologous stem cell transplantation,
for a hematological malignancy
Level II
Low-level laser therapy (wavelength at 650 nm,
power of 40 mW, and each square centimeter
treated with the required time to a tissue energy
dose of 2 J/cm2)
Prevention of
OM
Patients receiving HSCT conditioned with high-dose
chemotherapy, with or without TBI
Level II
Patient-controlled analgesia with morphine Pain reduction Patients undergoing HSCT Level II
Benzydamine mouthwash Prevention of
OM
Patients with HNC receiving moderate dose radiation therapy
(up to 50 Gy), without concomitant chemotherapy
Level II
Suggestions IN FAVOR of an intervention (weaker evidence supports effectiveness in the treatment setting listed):
Oral care protocols Prevention of
OM
All age groups and across all cancer treatment modalities Level III
Oral cryotherapy Prevention of
OM
Patients receiving high-dose melphalan, with or without
TBI, as conditioning for HSCT
Level III




Patients undergoing radiotherapy, without concomitant
chemotherapy, for HNC
Level III
Transdermal fentanyl Pain reduction Patients receiving conventional or high-dose chemotherapy,
with or without TBI
Level III
2 % morphine mouthwash Pain reduction Patients receiving chemoradiation for HNC Level III
0.5 % doxepin mouthwash Pain reduction All patients with OM-induced pain Level IV
Systemic zinc supplements administered orally Prevention of
OM
HNC patients receiving radiation therapy or chemoradiation Level III
Recommendations AGAINST interventions (strong evidence indicates lack of effectiveness in the treatment setting listed):
PTA (polymyxin, tobramycin, amphotericin B)
and BCoG (bacitracin, clotrimazole, gentamicin)
Prevention of
OM
Patients receiving radiation therapy for HNC Level II
Iseganan antimicrobial mouthwash Prevention of
OM
Patients receiving high-dose chemotherapy, with or
without TBI, for HSCT or in patients receiving
radiation therapy or concomitant chemoradiation for HNC
Level II
Iseganan antimicrobial mouthwash Prevention of
OM
Patients receiving high-dose chemotherapy, with or
without TBI, for HSCT or in patients receiving
radiation therapy or concomitant chemoradiation for HNC
Level II
Sucralfate mouthwash Prevention of
OM
Patients receiving chemotherapy for cancer (I), or inpatients
receiving radiation therapy (I) or concomitant chemoradiation
(II) for HNC
Level I, II
Sucralfate mouthwash Treatment of
OM
Patients receiving chemotherapy for cancer (I), or in
patients receiving radiation therapy (II) for HNC
Level I, II
Intravenous glutamine Prevention of
OM
Patients receiving high-dose chemotherapy, with
or without TBI, for HSCT
Level II
Suggestions AGAINST interventions (weaker evidence indicates lack of effectiveness in the treatment setting listed):
Chlorhexidine mouthwash Prevention of
OM





Patients receiving high-dose chemotherapy, for autologous or
allogeneic HSCT
Level II
Misoprostol mouthwash Prevention of
OM
Patients receiving radiation therapy for HNC Level III
Systemic pentoxifylline, administered orally Prevention of
OM
Patients undergoing HSCT Level III
Systemic pilocarpine, administered orally Prevention of
OM
Patients receiving radiation therapy for head and neck
cancer (III), or patients receiving high-dose chemotherapy,
with or without TBI, for HSCT (II)
Level II,
III
OM oral mucositis, μg microgram, kg kilogram, nm nanometer, mW milliwatt, J Joule, cm centimeter, Gy Gray, HSCT hematopoietic stem cell
transplantation, TBI total body irradiation, HNC head and neck cancer
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interventions and will reduce the burden of OM and other
toxicities associated with cancer treatment.
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